Search

Displaying results 4701 - 4710 of 7186 in total
  1. Drug

    G4544

    go.drugbank.com/drugs/DB05244
    Experimental

    G4544 is an oral gallium compound that enables oral absorption of the active ingredient contained in Ganite™ (gallium nitrate injection). It targets bone tissue and is actively incorporated into bone mineral at sites where bone is metabo...

  2. Drug

    Lortalamine

    go.drugbank.com/drugs/DB09187
    Experimental

    This drug never made it past clinical trials, likely due to ocular toxicity in animals, but has been used in positron emission tomography studies to label norepinephrine transporters.

  3. Drug

    Carbocromen

    go.drugbank.com/drugs/DB13279
    ApprovedWithdrawn

    Carbocromen was marketed for use in Germany as a vasodilator, however, it has been discontinued due to the risk of arrhythmia development [L5635].

  4. Drug

    IN01

    go.drugbank.com/drugs/DB16434
    Experimental

    Of note, the IN01 vaccine is being tested in a Phase I clinical trial in patients with fibrosing interstitial lung disease resulting from SARS-CoV-2 infection (NCT04537130). … The study will explore the effect of this vaccine on pulmonary function, oxygen saturation, quality of life, and fibrosing status in addition to biomarkers and molecular markers of the vaccine.

  5. Drug

    Elesclomol

    go.drugbank.com/drugs/DB05719
    Investigational

    In preclinical models elesclomol showed potent killing of a broad range of cancer cell types at high doses, and an ability to strongly enhance the efficacy of certain chemotherapy agents, with minimal … It is being developed by Synta Pharmaceuticals.

    Synonyms: 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide
  6. Drug

    Lumiracoxib

    go.drugbank.com/drugs/DB01283
    ApprovedWithdrawn

    On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver

  7. Drug

    H3B-8800

    go.drugbank.com/drugs/DB14017
    Investigational

    It offers the benefit of preferentially killing spliceosome-mutant cancer cells whereas other splicesome inhibitors, such as the pladienolide analogue E7107, show no such preferential targeting [A32749 … H3B-8800 is a novel spliceosome inhibitor developed by H3 Biomedicine [L2551].

  8. Drug

    Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells

    go.drugbank.com/drugs/DB15740
    Investigational

    In humans, OM-MSCs are derived from the olfactory mucosa which is collected in vivo through rhinoscopy techniques and nasal forceps. … Human olfactory mucosa-derived mesenchymal stem cells (OM-MSCs) reside in an accessible location of the nasal cavity and have properties of multipotency and high proliferation, which contributes to high

  9. Drug

    Alfacalcidol

    go.drugbank.com/drugs/DB01436
    ApprovedInvestigationalNutraceutical

    Alfacaldisol is activated by the enzyme 25-hydroxylase in the liver to mediate its effects in the body, or most importantly, the kidneys and bones.

    Synonyms: (5Z,7E)-9,10-seco-5,7,10(19)-cholestatrien-1α,3β-diol
  10. Drug

    Veligrotug

    go.drugbank.com/drugs/DB18976
    Approved

    depending on whether it is caught in the active inflammatory phase or has become chronic - Viridian describes veligrotug-vvze as the first approved treatment for the disease whose labeling includes data from